GSK2269557 ELLIPTA DPI
205759
Phase 1 small_molecule completed
Quick answer
GSK2269557 ELLIPTA DPI for Pulmonary Disease, Chronic Obstructive is a Phase 1 program (small_molecule) at GlaxoSmithKline with 1 ClinicalTrials.gov record(s).
Program details
- Company
- GlaxoSmithKline
- Indication
- Pulmonary Disease, Chronic Obstructive
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed